RLM Realm Thera.

TIDMRLM

RNS Number : 9097M

Realm Therapeutics PLC

02 May 2018

Realm Therapeutics plc

("Realm Therapeutics" or the "Company")

Annual Report and Accounts Available

2 May 2018 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics for immune-mediated diseases, confirms that, further to the announcement of its Final Results today, an electronic copy of the Annual Report and Accounts for the year ended 31 December 2017 is now available on the Company's website, www.realmtx.com

Contacts:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

Argot Partners

Stephanie Marks/Susan Kim

+1 212 600 1902

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSUUOARWBAVRAR

(END) Dow Jones Newswires

May 02, 2018 07:39 ET (11:39 GMT)

Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024

Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024